POS1236 IMPACT OF COVID-19 ON INITIATION AND RENEWAL OF BIOTHERAPIES AND TARGETED SYNTHETIC TREATMENTS

Background: During the epidemic’s peak of COVID-19, scientific societies published recommendations on biotherapy and targeted synthetic treatment (B/TST) use in patients with chronic articular inflammatory diseases, bowel psoriasis. Objectives: The objective was to evaluate impact COVID-19 France initiation renewal B/TST. Methods: LRx contains all anonymized medication dispenses prescribed outpatient care a representative panel French retails pharmacies, including data near 40 million patients. B/TST were studied using 2019 as reference dispense deliveries pharmacies regular flew order perform comparison. considered abatacept, anti-TNF, anti-IL6, anti-IL17, anti-IL12/23 or anti-IL23, JAK inhibitors (JAKi) other classes such aprelimast, aminosalicylates (AS), hydroxychloroquine (HCQ), methotrexate (MTX). A initiated defined not delivered past 12 months, conversely for renewal. Results presented raw one expressed percentage having at least delivery each therapeutic interest 2020 compared used year (period from week 19 corresponding lockdown period France). Results: period, decrease observed treated with: abatacept (405 vs 227 2020: -44%, p<0.001), anti-TNF (1156 1058, -31%, anti-IL17 (415 206, -50%, anti-IL12-23 (395 339, -12%, p=0.16), JAKi (289 174, -39%, p=0.006), contrasting an increase Tociliumab (117 445, +152%, p=0,01). We found 7% (2171 2015, p=0,35), 44% 227, 30% (3430 2390, p p<0.001) AS, aprelimast MTX initiation, respectively, 173% (1708 4671, p=0.11) HCQ initiation. No Conclusion: peak, MTX, biotherapies (except tocilizumab), dramatically decreased without impacting their Two treatments mainly initiated, tocilizumab probably due switch intravenous subcutaneous injection relation its presumably effect COVID-19. Overall, have been followed. Disclosure Interests: None declared